In our case, PD-1 inhibitor-involved maintenance therapy in patients with advanced iCCA was reported for the first time, and the combination provided a therapeutic strategy for clinical consideration. This evidence concerns the gene PDCD1 and infantile convulsions and choreoathetosis.